0000000000448355

AUTHOR

Chi-sheng Hung

showing 2 related works from this author

The association between new onset atrial fibrillation and incident cancer—A nationwide cohort study

2018

A recent analysis showed an association with new onset atrial fibrillation (NOAF) and incident cancer among women. We aimed to examine the risk of cancer among patients with NOAF in general population. A retrospective cohort of 5130 patients with NOAF was identified from a random sample of one million subjects between 2005 and 2010 from Taiwan National Health Insurance Research Database. The standard incidence ratio of incident cancer and hazard ratios were calculated by modeling cumulative incidence with competing risk of death. During a mean follow-up duration of 3.4 years, 330 patients developed cancer. The standard incidence ratio of all malignancies was 1.41 (95% confidence interval 1.…

MaleEconomicslcsh:MedicineSocial Sciences030204 cardiovascular system & hematologyVascular MedicineBrain Ischemia0302 clinical medicineRisk FactorsNeoplasmsEpidemiology of cancerAtrial FibrillationMedicine and Health SciencesGenitourinary CancersCumulative incidence030212 general & internal medicinelcsh:ScienceAged 80 and overeducation.field_of_studyMultidisciplinaryCancer Risk FactorsIncidenceHazard ratioAge FactorsMiddle AgedStrokeOncologyNeurologyFemaleArrhythmiaCohort studyResearch Articlemedicine.medical_specialtyCerebrovascular DiseasesUrologyPopulationCardiology03 medical and health sciencesBreast cancerHealth EconomicsSex FactorsDiagnostic MedicineInternal medicinemedicineCancer Detection and DiagnosisHumanseducationIschemic StrokeAgedColorectal Cancerbusiness.industrylcsh:RCancerCancers and NeoplasmsRetrospective cohort studymedicine.diseaseHealth CareWomen's Healthlcsh:QbusinessHealth InsuranceFollow-Up StudiesPLoS ONE
researchProduct

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

2021

OBJECTIVE: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. METHODS: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping ri…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyRegistryMedDRAPeripheral edemaClinical practicePulmonary arterial hypertensionRiociguatlaw.inventionPulmonary hypertension03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicine030212 general & internal medicineAdverse effectHipertensió pulmonarRiociguatbusiness.industrymedicine.diseasePulmonary hypertensionClinical trial030228 respiratory systemPulmonary hemorrhagemedicine.symptomSafetybusinessmedicine.drug
researchProduct